TAP Pharmaceutical Products, Inc. develops, commercializes, and markets pharmaceutical products in United States. It offers Lupron Depot leuprolide acetate for depot suspension for the treatment of prostate cancer, endometriosis and uterine fibroids, and central precocious puberty; and Prevacid lansoprazole for the short-term treatment of heartburn and other symptoms of gastroesophageal reflux disease, and symptom relief and maintenance of healed erosive esophagitis erosive esophagitis. The company was formerly known as Tap Holdings, Inc. and changed its name to TAP Pharmaceutical Products, Inc. in April 2000. The company was founded in 1977 and is headquartered in Lake Forest, Illinois. TAP Pharmaceutical Products, Inc. operates as a subsidiary of Abbott Laboratories and Takeda Pharmaceutical Co., Ltd.